Mark Brosius, who serves as the Executive Vice President and Chief Manufacturing and Supply Chain Officer at Intuitive Surgical Inc. (NASDAQ:ISRG), recently completed a series of transactions involving the sale of company common stock. The total value of these dispositions amounted to $15,945.
These sales were executed over two consecutive days, with the per-share prices ranging from $439.80 to $446.04. Specific details emerge from a Form 4 filing submitted to the Securities and Exchange Commission (SEC). On May 21, 2026, Mr. Brosius disposed of 18 shares of common stock at a price of $446.04 per share. The subsequent day, May 22, 2026, he sold an additional 18 shares at $439.80 each.
It is noted that the current trading price for ISRG common stock stands at $438.29. This figure places the stock near its 52-week low of $417.74, reflecting a year-to-date decline of 22.65%. The entirety of these recent sales were conducted under the framework of a pre-arranged trading plan. This established plan complies with SEC Rule 10b5-1 and is scheduled to expire on February 14, 2027.
Following the completion of these transactions, Mr. Brosius' direct ownership stake in Intuitive Surgical common stock was adjusted, leaving him holding 1,523 shares.
Company Valuation and Industry Standing
Intuitive Surgical operates within the medical device sector, representing a $155 billion industry player. The company currently trades at a Price-to-Earnings (P/E) ratio of 53.46. Analysis from InvestingPro indicates that despite market fluctuations, ISRG maintains its position as a significant entity within the Healthcare Equipment & Supplies industry. This analysis provides access to extensive research data for ISRG and over 1,400 other US stocks.
Recent Developments and Analyst Coverage
In terms of product development, Intuitive Surgical has announced substantial updates concerning its da Vinci 5 robotic surgical system. These enhancements include the addition of more than 100 new features, which are set to improve existing capabilities like Intuitive Telepresence. The deployment of these updates is scheduled for the U.S. market starting in June, though global availability remains contingent upon obtaining necessary regulatory approvals.
The company's recent financial performance has also drawn considerable attention from investment analysts. RBC Capital highlighted that ISRG exceeded expectations regarding both revenue and earnings per share (EPS). Specifically, the firm noted year-over-year growth of 23% in sales and a corresponding 38% increase in EPS.
Multiple major investment banks have adjusted their price targets for Intuitive Surgical. Piper Sandler lowered its target to $580 while maintaining an Overweight rating. Barclays similarly reduced its price target to $651, also maintaining an Overweight designation. Both firms cited the company's strong fundamental performance. Piper Sandler specifically pointed out that the first-quarter results surpassed consensus estimates, particularly concerning volume growth and placements. Meanwhile, Barclays attributed its positive assessment to robust underlying fundamentals driven by both procedures performed and system sales.
RBC Capital continues to support a favorable outlook with an Outperform rating, emphasizing the strong financial outcomes reported by the company.
Market Context
Looking at the broader market environment, software stocks experienced a selloff recently. Companies such as ServiceNow and IBM were among those affected following disappointing earnings reports. Although ServiceNow slightly surpassed Wall Street estimates, concerns arose regarding potential impacts from the U.S.-Iran war on subscription revenue streams. Conversely, IBM managed to beat both its earnings and revenue expectations; however, its shares declined after issuing unchanged guidance.